Alexander D. Verin
Research Subjects
Research Interests
Alexander D. Verin has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Natalia V. Bogatcheva
Medical College of Georgia, Vascular Biology Center, Augusta, GA 30912, USA
5 shared publications Alexander S. Antonov
Vascular Biology Center, Medical College of Georgia, Augusta, Georgia 30912, USA
2 shared publicationsGalina N. Antonova
Vascular Biology Center, Medical College of Georgia, Augusta, GA 30912
2 shared publicationsJohn D. Catravas
Vascular Biology Center, Medical College of Georgia, Augusta, GA 30912
2 shared publications- Rudolf Lucas
Vascular Biology Center, Augusta University, Augusta, GA 30912, USA
2 shared publications Agnieszka Jezierska
Vascular Biology Center, Medical College of Georgia, USA
1 shared publication
Latest Publications
- 1 September 2011
- Published by Bentham Science Publishers Ltd. in Current Signal Transduction Therapy
- Vol. 6 (3) , 428-440
Toll Like Receptors Signaling Pathways as a Target for Therapeutic Interventions
This review summarizes the key role of Toll-Like Receptor (TLRs) molecules for igniting the immune system. Activated by a broad spectrum of pathogens, cytokines or other specific molecules, TLRs trigger innate immune responses. Published data demonstrate that the targeting and suppression of TLRs and TLR-related proteins with particular inhibitors may provide pivotal treatments for patients with cancer, asthma, sepsis, Crohns disease and thrombosis. Many drugs that target cytokines act in the late phases of the activated pathways, after the final peptides, proteins or glycoproteins are formed in the cell environment. TLR activity occurs in the early activation of cellular pathways; consequently inhibiting them might be most beneficial in the treatment of human diseases.
- 1 September 2011
- Published by Bentham Science Publishers Ltd. in Current Signal Transduction Therapy
- Vol. 6 (3) , 428-440
Toll Like Receptors Signaling Pathways as a Target for Therapeutic Interventions
This review summarizes the key role of Toll-Like Receptor (TLRs) molecules for igniting the immune system. Activated by a broad spectrum of pathogens, cytokines or other specific molecules, TLRs trigger innate immune responses. Published data demonstrate that the targeting and suppression of TLRs and TLR-related proteins with particular inhibitors may provide pivotal treatments for patients with cancer, asthma, sepsis, Crohns disease and thrombosis. Many drugs that target cytokines act in the late phases of the activated pathways, after the final peptides, proteins or glycoproteins are formed in the cell environment. TLR activity occurs in the early activation of cellular pathways; consequently inhibiting them might be most beneficial in the treatment of human diseases.
- 4 April 2011
- Published by Wiley in Journal of Cellular Physiology
- Vol. 227 (2) , 759-771
Regulation of endothelial barrier function by TGF‐β type I receptor ALK5: Potential role of contractile mechanisms and heat shock protein 90
Multifunctional cytokine transforming growth factor‐beta (TGF‐β1) plays a critical role in the pathogenesis of acute lung inflammation by controlling endothelial monolayer permeability. TGF‐β1 regulates endothelial cell (EC) functions via two distinct receptors, activin receptor‐like kinase 1 (ALK1) and activin receptor‐like kinase 5 (ALK5). The precise roles of ALK1 and ALK5 in the regulation of TGF‐β1‐induced lung endothelium dysfunction remain mostly unknown. We now report that adenoviral infection with constitutively active ALK5 (caALK5), but not caALK1, induces EC retraction and that this receptor predominantly controls EC permeability. We demonstrate that ubiquitinated ALK5 and phosphorylated heat shock protein 27 (phospho‐Hsp27) specifically accumulate in the cytoskeleton fraction, which parallels with microtubule collapse, cortical actin disassembly and increased EC permeability. We have found that ALK1 and ALK5 interact with heat shock protein 90 (Hsp90). Moreover, the Hsp90 inhibitor radicicol (RA) prevents accumulation of ubiquitinated caALK5 and phospho‐Hsp27 in the cytoskeletal fraction and restore the decreased EC permeability induced by caALK5. We hypothesize that specific translocation of ubiquitinated ALK5 receptor into the cytoskeleton compartment due to its lack of degradation is the mechanism that causes the divergence of caALK1 and caALK5 signaling. J. Cell. Physiol. 227: 759–771, 2012.
- 4 April 2011
- Published by Wiley in Journal of Cellular Physiology
- Vol. 227 (2) , 759-771
Regulation of endothelial barrier function by TGF‐β type I receptor ALK5: Potential role of contractile mechanisms and heat shock protein 90
Multifunctional cytokine transforming growth factor‐beta (TGF‐β1) plays a critical role in the pathogenesis of acute lung inflammation by controlling endothelial monolayer permeability. TGF‐β1 regulates endothelial cell (EC) functions via two distinct receptors, activin receptor‐like kinase 1 (ALK1) and activin receptor‐like kinase 5 (ALK5). The precise roles of ALK1 and ALK5 in the regulation of TGF‐β1‐induced lung endothelium dysfunction remain mostly unknown. We now report that adenoviral infection with constitutively active ALK5 (caALK5), but not caALK1, induces EC retraction and that this receptor predominantly controls EC permeability. We demonstrate that ubiquitinated ALK5 and phosphorylated heat shock protein 27 (phospho‐Hsp27) specifically accumulate in the cytoskeleton fraction, which parallels with microtubule collapse, cortical actin disassembly and increased EC permeability. We have found that ALK1 and ALK5 interact with heat shock protein 90 (Hsp90). Moreover, the Hsp90 inhibitor radicicol (RA) prevents accumulation of ubiquitinated caALK5 and phospho‐Hsp27 in the cytoskeletal fraction and restore the decreased EC permeability induced by caALK5. We hypothesize that specific translocation of ubiquitinated ALK5 receptor into the cytoskeleton compartment due to its lack of degradation is the mechanism that causes the divergence of caALK1 and caALK5 signaling. J. Cell. Physiol. 227: 759–771, 2012.
- 26 November 2010
- Published by Wiley in Journal of Cellular Physiology
- Vol. 226 (2) , 469-476
αVβ3 integrin regulates macrophage inflammatory responses via PI3 kinase/Akt‐dependent NF‐κB activation
Controlling macrophage responses to pathogenic stimuli is critical for prevention of and recovery from the inflammatory state associated with the pathogenesis of many diseases. The adhesion receptor αVβ3 integrin is thought to be an important receptor that regulates macrophage differentiation and macrophage responses to external signaling, but it has not been previously identified as a contributor to macrophage‐related inflammation. Using an in vitro model of human blood monocytes (Mo) and monocyte‐derived macrophages (MDMs) we demonstrate that αVβ3 ligation results in sustained increases of the transcription factor NF‐κB DNA‐binding activity, as compared with control isotype‐matched IgG1. Activation of NF‐κB parallels the increase of NF‐κB‐dependent pro‐inflammatory cytokine mRNA expression in MDMs isolated from individual donors, for example, TNF‐α (8‐ to 28‐fold), IL‐1β (15‐ to 30‐fold), IL‐6 (2‐ to 4‐fold), and IL‐8 (5‐ to 15‐fold) whereas there is more than a 10‐fold decrease in IL‐10 mRNA level occurs. Upon ligation of the αVβ3 receptor, treatment with TNF‐α (10 ng/ml) or LPS (200 ng/ml, 1,000 EU) results in the enhanced and synergistic activation of NF‐κB and LPS‐induced TNF‐α secretion. As additional controls, an inhibitor of αVβ3 integrin, cyclic RGD (10 µg/ml; IC50 = 7.6 µM), attenuates the effects of αVβ3 ligation, and the natural ligand of αVβ3 integrin, vitronectin, reproduces the effects of αVβ3 activation by an immobilizing anti‐αVβ3 integrin mAb. We hypothesize that αVβ3 activation can maintain chronic inflammatory processes in pathological conditions and that the loss of αVβ3 ligation will allow macrophages to escape from the inflammatory state. J. Cell. Physiol. 226: 469–476, 2011.
- 26 November 2010
- Published by Wiley in Journal of Cellular Physiology
- Vol. 226 (2) , 469-476
αVβ3 integrin regulates macrophage inflammatory responses via PI3 kinase/Akt‐dependent NF‐κB activation
Controlling macrophage responses to pathogenic stimuli is critical for prevention of and recovery from the inflammatory state associated with the pathogenesis of many diseases. The adhesion receptor αVβ3 integrin is thought to be an important receptor that regulates macrophage differentiation and macrophage responses to external signaling, but it has not been previously identified as a contributor to macrophage‐related inflammation. Using an in vitro model of human blood monocytes (Mo) and monocyte‐derived macrophages (MDMs) we demonstrate that αVβ3 ligation results in sustained increases of the transcription factor NF‐κB DNA‐binding activity, as compared with control isotype‐matched IgG1. Activation of NF‐κB parallels the increase of NF‐κB‐dependent pro‐inflammatory cytokine mRNA expression in MDMs isolated from individual donors, for example, TNF‐α (8‐ to 28‐fold), IL‐1β (15‐ to 30‐fold), IL‐6 (2‐ to 4‐fold), and IL‐8 (5‐ to 15‐fold) whereas there is more than a 10‐fold decrease in IL‐10 mRNA level occurs. Upon ligation of the αVβ3 receptor, treatment with TNF‐α (10 ng/ml) or LPS (200 ng/ml, 1,000 EU) results in the enhanced and synergistic activation of NF‐κB and LPS‐induced TNF‐α secretion. As additional controls, an inhibitor of αVβ3 integrin, cyclic RGD (10 µg/ml; IC50 = 7.6 µM), attenuates the effects of αVβ3 ligation, and the natural ligand of αVβ3 integrin, vitronectin, reproduces the effects of αVβ3 activation by an immobilizing anti‐αVβ3 integrin mAb. We hypothesize that αVβ3 activation can maintain chronic inflammatory processes in pathological conditions and that the loss of αVβ3 ligation will allow macrophages to escape from the inflammatory state. J. Cell. Physiol. 226: 469–476, 2011.
- 1 May 2010
- Published by Elsevier in Vascular Pharmacology
- Vol. 52 (5-6) , 199-206
Molecular mechanisms involved in adenosine-induced endothelial cell barrier enhancement
- 1 May 2010
- Published by Elsevier in Vascular Pharmacology
- Vol. 52 (5-6) , 199-206
Molecular mechanisms involved in adenosine-induced endothelial cell barrier enhancement
- 1 March 2010
- Published by Springer Nature
- p. 39-55
Extracellular Purines in Endothelial Cell Barrier Regulation
- 1 March 2010
- Published by Springer Nature
- p. 39-55
Extracellular Purines in Endothelial Cell Barrier Regulation
- 1 January 2009
- Published by Elsevier in Microvascular Research
- Vol. 77 (1) , 64-69
Reprint of “The role of cytoskeleton in the regulation of vascular endothelial barrier function” [Microvascular Research 76 (2008) 202–207]
- 1 January 2009
- Published by Elsevier in Microvascular Research
- Vol. 77 (1) , 64-69
Reprint of “The role of cytoskeleton in the regulation of vascular endothelial barrier function” [Microvascular Research 76 (2008) 202–207]
- 1 November 2008
- Published by Elsevier in Microvascular Research
- Vol. 76 (3) , 202-207
The role of cytoskeleton in the regulation of vascular endothelial barrier function
- 1 November 2008
- Published by Elsevier in Microvascular Research
- Vol. 76 (3) , 202-207
The role of cytoskeleton in the regulation of vascular endothelial barrier function
- 1 September 2008
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 295 (3) , L440-L450
TIMAP is a positive regulator of pulmonary endothelial barrier function
TGF-β-inhibited membrane-associated protein, TIMAP, is expressed at high levels in endothelial cells (EC). It is regarded as a member of the MYPT (myosin phosphatase target subunit) family of protein phosphatase 1 (PP1) regulatory subunits; however, its function in EC is not clear. In our pull-down experiments, recombinant TIMAP binds preferentially the β-isoform of the catalytic subunit of PP1 (PP1cβ) from pulmonary artery EC. As PP1cβ, but not PP1cα, binds with MYPT1 into functional complex, these results suggest that TIMAP is a novel regulatory subunit of myosin phosphatase in EC. TIMAP depletion by small interfering RNA (siRNA) technique attenuates increases in transendothelial electrical resistance induced by EC barrier-protective agents (sphingosine-1-phosphate, ATP) and enhances the effect of barrier-compromising agents (thrombin, nocodazole) demonstrating a barrier-protective role of TIMAP in EC. Immunofluorescent staining revealed colocalization of TIMAP with membrane/cytoskeletal protein, moesin. Moreover, TIMAP coimmunoprecipitates with moesin suggesting the involvement of TIMAP/moesin interaction in TIMAP-mediated EC barrier enhancement. Activation of cAMP/PKA cascade by forskolin, which has a barrier-protective effect against thrombin-induced EC permeability, attenuates thrombin-induced phosphorylation of moesin at the cell periphery of control siRNA-treated EC. On the contrary, in TIMAP-depleted EC, forskolin failed to affect the level of moesin phosphorylation at the cell edges. These results suggest the involvement of TIMAP in PKA-mediated moesin dephosphorylation and the importance of this dephosphorylation in TIMAP-mediated EC barrier protection.
- 1 September 2008
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 295 (3) , L440-L450
TIMAP is a positive regulator of pulmonary endothelial barrier function
TGF-β-inhibited membrane-associated protein, TIMAP, is expressed at high levels in endothelial cells (EC). It is regarded as a member of the MYPT (myosin phosphatase target subunit) family of protein phosphatase 1 (PP1) regulatory subunits; however, its function in EC is not clear. In our pull-down experiments, recombinant TIMAP binds preferentially the β-isoform of the catalytic subunit of PP1 (PP1cβ) from pulmonary artery EC. As PP1cβ, but not PP1cα, binds with MYPT1 into functional complex, these results suggest that TIMAP is a novel regulatory subunit of myosin phosphatase in EC. TIMAP depletion by small interfering RNA (siRNA) technique attenuates increases in transendothelial electrical resistance induced by EC barrier-protective agents (sphingosine-1-phosphate, ATP) and enhances the effect of barrier-compromising agents (thrombin, nocodazole) demonstrating a barrier-protective role of TIMAP in EC. Immunofluorescent staining revealed colocalization of TIMAP with membrane/cytoskeletal protein, moesin. Moreover, TIMAP coimmunoprecipitates with moesin suggesting the involvement of TIMAP/moesin interaction in TIMAP-mediated EC barrier enhancement. Activation of cAMP/PKA cascade by forskolin, which has a barrier-protective effect against thrombin-induced EC permeability, attenuates thrombin-induced phosphorylation of moesin at the cell periphery of control siRNA-treated EC. On the contrary, in TIMAP-depleted EC, forskolin failed to affect the level of moesin phosphorylation at the cell edges. These results suggest the involvement of TIMAP in PKA-mediated moesin dephosphorylation and the importance of this dephosphorylation in TIMAP-mediated EC barrier protection.
- 3 September 2007
- Published by Cambridge University Press (CUP)
- p. 737-745
Mitogen-Activated Protein Kinases
- 3 September 2007
- Published by Cambridge University Press (CUP)
- p. 737-745
Mitogen-Activated Protein Kinases
- 1 November 2003
- Published by SAGE Publications in Journal of Investigative Medicine
- Vol. 51 (6) , 341-352
Mitogen-Activated Protein Kinases in Endothelial Pathophysiology
- 1 November 2003
- Published by SAGE Publications in Journal of Investigative Medicine
- Vol. 51 (6) , 341-352
Mitogen-Activated Protein Kinases in Endothelial Pathophysiology